N2DY

N2DY is a generic drug candidate developed by GL Pharm Tech for use in antiretroviral therapy (ART). It is categorized within the company's generic drug pipeline, indicating it is intended to be a bioequivalent version of an existing, off-patent antiretroviral medication used for the treatment of viral infections such as HIV. As a generic ART product, it likely functions by inhibiting key stages of the viral life cycle, such as entry, reverse transcription, integration, or protein cleavage, though the specific active pharmaceutical ingredient (API) is not disclosed in the company's public pipeline documentation.